Susceptibility genes for Kawasaki disease: Toward implementation of personalized medicine

Journal of Human Genetics

Volumn 54, Issue 2, 2009, Pages 67-73

  Hata, Akira ^a   Onouchi, Yoshihiro ^b  

^a CHIBA UNIVERSITY   (Japan)

^b RIKEN   (Japan)

Author keywords

Coronary artery legions; Inositol 1,4,5 trisphosphate 3 kinase C; Kawasaki's disease; Personalized medicine

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOGLOBULIN; INOSITOL TRISPHOSPHATE 3 KINASE; METHOTREXATE; METHYLPREDNISOLONE; ULINASTATIN; INOSITOL 1,4,5-TRISPHOSPHATE 3-KINASE; PHOSPHOTRANSFERASE;

CARDIOVASCULAR DISEASE; CHROMOSOME 19; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; GENE MAPPING; GENETIC LINKAGE; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HUMAN; MORTALITY; MUCOCUTANEOUS LYMPH NODE SYNDROME; PATHOGENESIS; REVIEW; SIBLING; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; GENE LINKAGE DISEQUILIBRIUM; GENETICS; PERSONALIZED MEDICINE;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDIVIDUALIZED MEDICINE; LINKAGE DISEQUILIBRIUM; MUCOCUTANEOUS LYMPH NODE SYNDROME; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); SIGNAL TRANSDUCTION;

EID: 60749111041     PISSN: 14345161     EISSN: None     Source Type: Journal    
DOI: 10.1038/jhg.2008.9     Document Type: Review

References (83)

1. Kawasaki, T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes: a clinical observation (in Japanese). Jpn. J. Allergy 16, 178-222 (1967).
2. Burns, J. C. Commentary: translation of Dr Tomisaku Kawasaki's original report of fifty patients in 1967. Pediatr. Infect. Dis. J. 21, 993-995 (2002).
3. Kawasaki, T., Kosaki, F., Okawa, S., Shigematsu, I. & Yanagawa, H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 54, 271-276 (1974).
4. Dean, A. G., Melish, M. E., Hicks, R. & Palumbo, N. E. An epidemic of Kawasaki syndrome in Hawaii. J. Pediatr. 100, 552-557 (1982).
5. Nakamura, Y., Yashiro, M., Uehara, R., Oki, I., Watanabe, M. & Yanagawa, H. Epidemiologic features of Kawasaki disease in Japan: results from the nationwide survey in 2005-2006. J. Epidemiol. 18, 167-172 (2008).
6. Du, Z. D., Zhao, D., Du, J., Zhang, Y. L., Lin, Y., Liu, C. et al. Epidemiological study on Kawasaki disease in Beijing from 2000 through 2004. Pediatr. Infect. Dis. J. 26, 449-451 (2007).
7. Huang, G. Y., Ma, X. J., Huang, M., Chen, S. B., Huang, M. R., Gui, Y. H. et al. Epidemiologic pictures of Kawasaki disease in Shanghai from 1998 through 2002. J. Epidemiol. 16, 9-14 (2006).
8. Chang, L. Y., Chang, I. S., Lu, C. Y., Chiang, B. L., Lee, C. Y., Chen, P. J. et al. Epidemiological features of Kawasaki disease in Taiwan, 1996-2002. Pediatrics 114, e678-e682 (2004).
9. Park, Y. W., Han, J. W., Park, I. S., Kim, C. H., Yun, Y. S., Cha, S. H. et al. Epidemiologic study of Kawasaki disease in Korea, 2000-2002. Pediatric. Int. 47, 382-387 (2005).
10. Holman, R. C., Curns, A. T., Belay, E. D., Steiner, C. A., Effler, P. V., Yorita, K. L. et al. Kawasaki syndrome in Hawaii. Pediatr. Infect. Dis. J. 24, 429-433 (2005).
11. Holman, R. C., Shahriari, A., Effler, P. V., Belay, E. D. & Schonberger, L. B. Kawasaki syndrome hospitalizations among children in Hawaii and Connecticut. Arch. Pediatr. Adolesc. Med. 154, 804-808 (2000).
12. Kato, H., Koike, S., Yamamoto, M., Ito, Y. & Yano, E. Coronary aneurysms in infants and young children with acute febrile mucocutaneous lymph node syndrome. J. Pediatr. 86, 892-898 (1975).
13. Kato, H., Sugimura, T., Akagi, T., Sato, N., Hashino, K., Maeno, Y. et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation 94, 1379-1385 (1996).
14. Furusho, K., Kamiya, T., Nakano, H., Kiyosawa, N., Shinomiya, K., Hayashidera, T. et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 2, 1055-1058 (1984).
15. Newburger, J. W., Takahashi, M., Beiser, A. S., Burns, J. C., Bastian, J., Chung, K. J. et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N. Engl. J. Med. 324, 1633-1639 (1991).
16. Terai, M. & Shulman, S. T. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J. Pediatr. 131, 888-893 (1997).
17. Kobayashi, T., Inoue, Y., Takeuchi, K., Okada, Y., Tamura, K., Tomomasa, T. et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 113, 2606-2612 (2006).
18. Cook, D. H., Antia, A., Attie, F., Gersony, W. M., Kamiya, T., Kato, H. et al. Results from an international survey of Kawasaki disease in 1979-82. Can. J. Cardiol. 5, 389-394 (1989).
19. Fujita, Y., Nakamura, Y., Sakata, K., Hara, N., Kobayashi, M., Nagai, M. et al. Kawasaki disease in families. Pediatrics 84, 666-669 (1989).
20. Uehara, R., Yashiro, M., Nakamura, Y. & Yanagawa, H. Kawasaki disease in parents and children. Acta Paediatr. 92, 694-697 (2003).
21. Uehara, R., Yashiro, M., Nakamura, Y. & Yanagawa, H. Clinical features of patients with Kawasaki disease whose parents had the same disease. Arch. Pediatr. Adolesc. Med. 158, 1166-1169 (2004).
22. Dergun, M., Kao, A., Hauger, S. B., Newburger, J. W. & Burns, J. C. Familial occurrence of Kawasaki syndrome in North America. Arch. Pediatr. Adolesc. Med. 159, 876-881 (2005).
23. Onouchi, Y. Kawasaki disease calcium/NFAT susceptibility pathway and other genetic variants linked to susceptibility and outcome. Pediatr. Res. (in press).
24. Matsuda, I., Hattori, S., Nagata, N., Fruse, A. & Nambu, H. HLA antigens in mucocutaneous lymph node syndrome. Am. J. Dis. Child. 131, 1417-1418 (1977).
25. Kato, S., Kimura, M., Tsuji, K., Kusakawa, S., Asai, T., Juji, T. et al. HLA antigens in Kawasaki disease. Pediatrics 61, 252-255 (1978).
26. Krensky, A. M., Berenberg, W., Shanley, K. & Yunis, E. J. HLA antigens in mucocutaneous lymph node syndrome in New England. Pediatrics 67, 741-743 (1981).
27. Krensky, A. M., Grady, S., Shanley, K. M., Berenberg, W. & Yunis, E. J. Epidemic and endemic HLA-B and DR associations in mucocutaneous lymph node syndrome. Hum. Immunol. 6, 75-77 (1983).
28. Keren, G., Danon, Y. L., Orgad, S., Kalt, R. & Gazit, E. HLA Bw51 is increased in mucocutaneous lymph node syndrome in Israeli patients. Tissue Antigens 20, 144-146 (1982).
29. Chang, C. C., Hawkins, B. R., Kao, H. K., Chow, C. B. & Lau, Y. L. Human leucocyte antigens in southern Chinese with Kawasaki disease. Eur. J. Pediatr. 151, 866 (1992).
30. Oh, J. H., Han, J. W., Lee, S. J., Lee, K. Y., Suh, B. K., Koh, D. K. et al. Polymorphisms of human leukocyte antigen genes in Korean children with Kawasaki disease. Pediatr. Cardiol. 29, 402-408 (2008).
31. Onouchi, Y., Tamari, M., Takahashi, A., Tsunoda, T., Yashiro, M., Nakamura, Y. et al. A genomewide linkage analysis of Kawasaki disease: evidence for linkage to chromosome 12. J. Hum. Genet. 52, 179-190 (2007).
32. Burns, J. C., Shimizu, C., Gonzalez, E., Kulkarni, H., Patel, S., Shike, H. et al. Genetic variations in the receptor-ligand pair CCR5 and CCL3L1 are important determinants of susceptibility to Kawasaki disease. J. Infect. Dis. 192, 344-349 (2005).
33. Jhang, W. K., Kang, M. J., Jin, H. S., Yu, J., Kim, B. J., Kim, B. S. et al. The CCR5 (-2135C/T) polymorphism may be associated with the development of Kawasaki disease in Korean children. J. Clin. Immunol. (e-pub ahead of print 15 July 2008).
34. Breunis, W. B., Biezeveld, M. H., Geissler, J., Kuipers, I. M., Lam, J., Ottenkamp, J. et al. Polymorphisms in chemokine receptor genes and susceptibility to Kawasaki disease. Clin. Exp. Immunol. 150, 83-90 (2007).
35. Jibiki, T., Terai, M., Shima, M., Ogawa, A., Hamada, H., Kanazawa, M. et al. Monocyte chemoattractant protein 1 gene regulatory region polymorphism and serum levels of monocyte chemoattractant protein 1 in Japanese patients with Kawasaki disease. Arthritis Rheum. 44, 2211-2212 (2001).
36. Burns, J. C., Shimizu, C., Shike, H., Newburger, J. W., Sundel, R. P., Baker, A. L. et al. Family-based association analysis implicates IL-4 in susceptibility to Kawasaki disease. Genes Immun. 6, 438-444 (2005).
37. Wu, S. F., Chang, J. S., Wan, L., Tsai, C. H. & Tsai, F. J. Association of IL-1Ra gene polymorphism, but no association of IL-1beta and IL-4 gene polymorphisms, with Kawasaki disease. J. Clin. Lab. Anal. 19, 99-102 (2005).
38. Huang, F. Y., Chang, T. Y., Chen, M. R., Lee, H. C., Chiu, N. C., Chi, H. et al. The -590 C/T and 8375 A/G interleukin-4 polymorphisms are not associated with Kawasaki disease in Taiwanese children. Hum. Immunol. 69, 52-57 (2008).
39. Sohn, M. H., Hur, M. W. & Kim, D. S. Interleukin 6 gene promoter polymorphism is not associated with Kawasaki disease. Genes Immun. 2, 357-362 (2001).
40. Hsueh, K. C., Lin, Y. J., Chang, J. S., Wan, L., Tsai, Y. H., Tsai, C. H. et al. Influence of interleukin 18 promoter polymorphisms in susceptibility to Kawasaki disease in Taiwan. J. Rheumatol. 35, 1408-1413 (2008).
41. Jin, H. S., Kim, H. B., Kim, B. S., Lee, J. K., Seo, E. J., Yoo, H. W. et al. The IL-10 (-627 A/C) promoter polymorphism may be associated with coronary aneurysms and low serum albumin in Korean children with Kawasaki disease. Pediatr. Res. 61, 584-587 (2007).
42. Kariyazono, H., Ohno, T., Khajoee, V., Ihara, K., Kusuhara, K., Kinukawa, N. et al. Association of vascular endothelial growth factor (VEGF) and VEGF receptor gene polymorphisms with coronary artery lesions of Kawasaki disease. Pediatr. Res. 56, 953-959 (2004).
43. Breunis, W. B., Biezeveld, M. H., Geissler, J., Ottenkamp, J., Kuipers, I. M., Lam, J. et al. Vascular endothelial growth factor gene haplotypes in Kawasaki disease. Arthritis Rheum. 54, 1588-1594 (2006).
44. Hsueh, K. C., Lin, Y. J., Chang, J. S., Wan, L., Tsai, Y. H., Tsai, C. H. et al. Association of vascular endothelial growth factor C-634 g polymorphism in Taiwanese children with Kawasaki disease. Pediatr. Cardiol. 29, 292-296 (2008).
45. Huang, F. Y., Chang, T. Y., Chen, M. R., Lee, H. C., Chi, H., Chiu, N. C. et al. Lack of association of the vascular endothelial growth factor gene polymorphisms with Kawasaki disease in Taiwanese children. J. Clin. Immunol. 28, 322-328 (2008).
46. Kamizono, S., Yamada, A., Higuchi, T., Kato, H. & Itoh, K. Analysis of tumor necrosis factor-alpha production and polymorphisms of the tumor necrosis factor-alpha gene in individuals with a history of Kawasaki disease. Pediatr. Int. 41, 341-345 (1999).
47. Quasney, M. W., Bronstein, D. E., Cantor, R. M., Zhang, Q., Stroupe, C., Shike, H. et al. Increased frequency of alleles associated with elevated tumor necrosis factor-alpha levels in children with Kawasaki disease. Pediatr. Res. 49, 686-690 (2001).
48. Chien, Y. H., Chang, K. W., Yang, Y. H., Lu, M. Y., Lin, Y. T. & Chiang, B. L. Association between levels of TNF-alpha and TNF-alpha promoter -308 A/A polymorphism in children with Kawasaki disease. J. Formos. Med. Assoc. 102, 147-150 (2003).
49. Ahn, S. Y., Jang, G. C., Shin, J. S., Shin, K. M. & Kim, D. S. Tumor necrosis factor-alpha levels and promoter polymorphism in patients with Kawasaki disease in Korea. Yonsei Med. J. 44, 1021-1026 (2003).
50. Cheung, Y. F., Huang, G. Y., Chen, S. B., Liu, X. Q., Xi, L., Liang, X. C. et al. Inflammatory gene polymorphisms and susceptibility to Kawasaki disease and its arterial sequelae. Pediatrics 122, e608-e614 (2008).
51. Onouchi, Y., Onoue, S., Tamari, M., Wakui, K., Fukushima, Y., Yashiro, M. et al. CD40 ligand gene and Kawasaki disease. Eur. J. Hum. Genet. 12, 1062-1068 (2004).
52. Huang, F. Y., Chang, T. Y., Chen, M. R., Chiu, N. C., Chi, H., Lee, H. C. et al. Genetic polymorphisms in the CD40 ligand gene and Kawasaki disease. J. Clin. Immunol. 28, 405-410 (2008).
53. Biezeveld, M. H., Kuipers, I. M., Geissler, J., Lam, J., Ottenkamp, J. J., Hack, C. E. et al. Association of mannose-binding lectin genotype with cardiovascular abnormalities in Kawasaki disease. Lancet 361, 1268-1270 (2003).
54. Cheung, Y. F., Huang, G. Y., Chen, S. B., Liu, X. Q., Xi, L., Liang, X. C. et al. Inflammatory gene polymorphisms and susceptibility to Kawasaki disease and its arterial sequelae. Pediatrics 122, e608-e614 (2008).
55. Biezeveld, M. H., Geissler, J., Weverling, G. J., Kuipers, I. M., Lam, J., Ottenkamp, J. et al. Polymorphisms in the mannose-binding lectin gene as determinants of age-defined risk of coronary artery lesions in Kawasaki disease. Arthritis Rheum. 54, 369-376 (2006).
56. Cheung, Y. F., Ho, M. H., Ip, W. K., Fok, S. F., Yung, T. C. & Lau, Y. L. Modulating effects of mannose binding lectin genotype on arterial stiffness in children after Kawasaki disease. Pediatr. Res. 56, 591-596 (2004).
57. Park, J. A., Shin, K. S. & Kim, Y. W. Polymorphism of matrix metalloproteinase-3 promoter gene as a risk factor for coronary artery lesions in Kawasaki disease. J. Korean Med. Sci. 20, 607-611 (2005).
58. Ikeda, K., Ihara, K., Yamaguchi, K., Muneuchi, J., Ohno, T., Mizuno, Y. et al. Genetic analysis of MMP gene polymorphisms in patients with Kawasaki disease. Pediatr. Res. 63, 182-185 (2008).
59. Furuno, K., Takada, H., Yamamoto, K., Ikeda, K., Ohno, T., Khajoee, V. et al. Tissue inhibitor of metalloproteinase 2 and coronary artery lesions in Kawasaki disease. J. Pediatr. 151, 155-160 (2007).
60. Tsukahara, H., Hiraoka, M., Saito, M., Nishida, K., Kobata, R., Tsuchida, S. et al. Methylenetetrahydrofolate reductase polymorphism in Kawasaki disease. Pediatr. Int. 42, 236-240 (2000).
61. Khajoee, V., Kariyazono, H., Ohno, T., Ihara, K., Mizuno, Y., Kusuhara, K. et al. Inducible and endothelial constitutive nitric oxide synthase gene polymorphisms in Kawasaki disease. Pediatr. Int. 45, 130-134 (2003).
62. Wu, S. F., Chang, J. S., Peng, C. T., Shi, Y. R. & Tsai, F. J. Polymorphism of angiotensin-1 converting enzyme gene and Kawasaki disease. Pediatr. Cardiol. 25, 529-533 (2004).
63. Shim, Y. H., Kim, H. S., Sohn, S. & Hong, Y. M. Insertion/deletion polymorphism of angiotensin converting enzyme gene in Kawasaki disease. J. Korean Med. Sci. 21, 208-211 (2006).
64. Fukazawa, R., Sonobe, T., Hamamoto, K., Hamaoka, K., Sakata, K., Asano, T. et al. Possible synergic effect of angiotensin-I converting enzyme gene insertion/deletion polymorphism and angiotensin-II type-1 receptor 1166A/C gene polymorphism on ischemic heart disease in patients with Kawasaki disease. Pediatr. Res. 56, 597-601 (2004).
65. Takeuchi, K., Yamamoto, K., Kataoka, S., Kakihara, T., Tanaka, A., Sato, S. et al. High incidence of angiotensin I converting enzyme genotype II in Kawasaki disease patients with coronary aneurysm. Eur. J. Pediatr. 156, 266-268 (1997).
66. Nishimura, S., Zaitsu, M., Hara, M., Yokota, G., Watanabe, M., Ueda, Y. et al. A polymorphism in the promoter of the CD14 gene (CD14/-159) is associated with the development of coronary artery lesions in patients with Kawasaki disease. J. Pediatr. 143, 357-362 (2003).
67. Taniuchi, S., Masuda, M., Teraguchi, M., Ikemoto, Y., Komiyama, Y., Takahashi, H. et al. Polymorphism of Fc gamma RIIa may affect the efficacy of gamma-globulin therapy in Kawasaki disease. J. Clin. Immunol. 25, 309-313 (2005).
68. Biezeveld, M., Geissler, J., Merkus, M., Kuipers, I. M., Ottenkamp, J. & Kuijpers, T. The involvement of Fc gamma receptor gene polymorphisms in Kawasaki disease. Clin. Exp. Immunol. 147, 106-111 (2007).
69. Ouchi, K., Suzuki, Y., Shirakawa, T. & Kishi, F. Polymorphism of SLC11A1 (formerly NRAMP1) gene confers susceptibility to Kawasaki disease. J. Infect. Dis. 187, 326-329 (2003).
70. Minami, T., Suzuki, H., Takeuchi, T., Uemura, S., Sugatani, J. & Yoshikawa, N. A polymorphism in plasma platelet-activating factor acetylhydrolase is involved in resistance to immunoglobulin treatment in Kawasaki disease. J. Pediatr. 147, 78-83 (2005).
71. Kanai, M., Tanabe, S., Okada, M., Suzuki, H., Niki, T., Katsuura, M. et al. Polymorphisms of heme oxygenase-1 and bilirubin UDP-glucuronosyltransferase genes are not associated with Kawasaki disease susceptibility. Tohoku J. Exp. Med. 200, 155-159 (2003).
72. Huang, Y., Lee, Y. J., Chen, M. R., Hsu, C. H., Lin, S. P., Sung, T. C. et al. Polymorphism of transmembrane region of MICA gene and Kawasaki disease. Exp. Clin. Immunogenet. 17, 130-137 (2000).
73. Furukawa, S., Matsubara, T., Jujoh, K., Yone, K., Sugawara, T., Sasai, K. et al. Peripheral blood monocyte/macrophages and serum tumor necrosis factor in Kawasaki disease. Clin. Immunol. Immunopathol. 48, 247-251 (1988).
74. Maury, C. P., Salo, E. & Pelkonen, P. Elevated circulating tumor necrosis factoralpha in patients with Kawasaki disease. J. Lab. Clin. Med. 113, 651-654 (1989).
75. Matsubara, T., Furukawa, S. & Yabuta, K. Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronaryartery lesions. Clin. Immunol. Immunopathol. 56, 29-36 (1990).
76. Weiss, J. E., Eberhard, B. A., Chowdhury, D. & Gottlieb, B. S. Infliximab as a novel therapy for refractory Kawasaki disease. J. Rheumatol. 31, 808-810 (2004).
77. Burns, J. C., Best, B. M., Mejias, A., Mahony, L., Fixler, D. E., Jafri, H. S. et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J. Pediatr. 153, 833-838 (2008).
78. Saji, T. & Kemmotsu, Y. Infliximab for Kawasaki syndrome. J. Pediatr. 149, 426 (2006).
79. Onouchi, Y., Gunji, T., Burns, J. C., Shimizu, C., Newburger, J. W., Yashiro, M. et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat. Genet. 40, 35-42 (2008).
80. Rao, A., Luo, C. & Hogan, P. G. Transcription factors of the NFAT family: regulation and function. Annu. Rev. Immunol. 15, 707-747 (1997).
81. Crabtree, G. R. & Olson, E. N. NFAT signaling: choreographing the social lives of cells. Cell 109 (Suppl), S67-S79 (2002).
82. Macian, F. NFAT proteins: key regulators of T-cell development and function. Nat. Rev. Immunol. 5, 472-484 (2005).
83. Liu, R., McEachin, R. C. & States, D. J. Computationally identifying novel NF-kappa B-regulated immune genes in the human genome. Genome Res. 13, 654-661 (2003).